

## PROGRAM CME INFORMATION

### Renal Genetics in 2025 and Beyond: What's Ahead for this Emerging and Dynamic Field

*Release Date: March 7, 2025*

*Expiration Date: March 7, 2026*

This activity is jointly provided by Global Education Group and KDIGO.

This activity is supported by an educational grant from Natera.

#### **Target Audience**

The educational design of this activity addresses the needs of nephrologists and related specialists and allied health professionals involved in genetics and the treatment of patients with chronic kidney disease.

#### **Program Overview**

Join Professors Andrew Mallett, Nine V.A.M. Knoers, Matthew Sampson, and Ulla Schultheiss in the fourth module of this webinar series. In this state of the art webinar, speakers will discuss the future of genetic testing in nephrology. This webinar will address how the field of genetic testing has evolved, polygenic risk scores, and the future of precision therapies in genetic kidney disease.

#### **Educational Objectives**

*After completing this activity, the participant should be better able to:*

- Discuss optimal evaluation and interpretation of testing results
- Describe the clinical utility of employing genetic testing in nephrology
- Explain the limitations to genetic testing modalities
- List the steps in the genetic testing process

#### **Webinar Participants**

- **Andrew Mallett, MBBS, MMed, PhD, CF, AFRACMA, FASN, FRACP – Moderator**  
Director of Clinical Research & Nephrologist  
Townsville University Hospital  
Australia
  - Relevant financial relationships:
    - *Consulting Fee (e.g., Advisory Board): Advisory Board - GSK*
    - *Contracted Research: Sanofi*
    - *Other (Describe): Travel Support - Otsuka*
- **Nine V.A.M. Knoers, MD, PhD – Speaker**  
Head of Department of Genetics  
University Medical Centre Groningen  
The Netherlands
  - Relevant financial relationships:
    - *Other (Describe): Alnylam - travel and accommodation reimbursement*

- **Matthew Sampson, MD – Speaker**  
Associate Professor of Pediatrics  
Harvard University  
United States
  - Relevant financial relationships:
    - *Consulting Fee (e.g., Advisory Board): Naterra*
- **Ulla Schultheiss, MD - Speaker**  
Faculty of Medicine  
Institute of Genetic Epidemiology  
University of Freiburg  
Germany
  - Relevant financial relationships: *Nothing to disclose*

### **Physician Accreditation Statement**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and KDIGO. Global is accredited by the ACCME to provide continuing medical education for physicians.

### **Physician Credit Designation**

Global Education Group designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### **Instructions to Receive Credit**

In order to receive credit for this activity, the participant must watch the content video in its entirety, answer the posttest questions with 70% or better, and complete the program evaluation. The program posttest/evaluation QR code will be provided at the conclusion of the content video and a link for the same thing will be provided in the comments section below the video. CME certificates will be emailed within 3-4 weeks of eval completion.

### **Fee Information& Refund/Cancellation Policy**

There is no fee to participate in the webinar.

### **Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.



The ***planners and managers*** at Global Education Group and KDIGO don't have any relevant financial relationships with ineligible companies to disclose.

#### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and KDIGO do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

#### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.